Clinical Trials (Phase III)
Filter News
Found 14,090 articles
-
AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).
-
This morning, Genentech released results of its Phase III IMpower 133 trial that showed treatment with Tecentriq plus chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer than with chemotherapy alone.
-
Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society
9/25/2018
Intec Pharma Ltd. today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson's and Movement Disorder Society (MDS 2018) being held from October 5-9, 2018 in Hong Kong.
-
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
9/25/2018
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS)
-
IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefit in Unresectable, Stage III Lung Cancer
9/25/2018
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy
9/25/2018
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the initiation of PolarisDMD, the Company’s Phase 3 trial for edasalonexent in Duchenne muscular dystrophy (DMD).
-
Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections
9/25/2018
Atox Bio today announced the independent Data Monitoring Committee (DMC) completed its pre-planned safety review of the first 200 patients enrolled in the company's ACCUTE trial
-
Physicians have long recommended fish oil to patients with high cholesterol and triglycerides, even though the scientific studies on it are mixed. Amarin developed a drug called Vascepa, which derives from a purified component of fish oil called eicosapentaenoic acid (EPA).
-
AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
-
Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neur...
9/24/2018
Soliris® Reduced the Risk of Adjudicated On-Trial Relapse by 94.2% Compared to Placebo (p < 0.0001). -
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung Cancer
9/24/2018
Data will be presented at the 2018 World Conference on Lung Cancer (WCLC) and also featured in the WCLC press program on September 24, 2018
-
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
-
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
9/21/2018
Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression
-
Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018
9/20/2018
Biomarker Data Show that Molecular Target of Vicinium™, EpCAM, Expressed in Nearly All High-Grade NMIBC Patients
-
Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anaemia not on Dialysis
9/20/2018
Astellas Pharma Inc. today announced that roxadustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase activity, met its primary endpoints in the Phase 3 ALPS study
-
AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.
-
Zealand Pharma’s Phase III Severe Hypoglycemia Rescue Treatment Hits the Mark in Clinical Trial
9/19/2018
Days after selling future royalty streams for two Sanofi diabetes drugs for $205 million, Denmark-based Zealand Pharma announced its Phase III trial for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints that sets up potential regulatory approval. -
Privately-held Galera Therapeutics, Inc. secured $150 million in a Series C funding round that will be used to drive its experimental head and neck cancer treatment GC4419 into Phase III trials, as well as support pre-commercialization activities.
-
MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R)Improves Long-Term Patient-Reported Outcomes in Patients with Moderate to Severe Plaque Psoriasis
9/19/2018
MorphoSys AG announced today that its licensee Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) has announced new data that, according to a press released issued by Janssen on September 12, 2018
-
ApoCell Announces Publication of First Therapeutic Target Biomarker Correlation in Circulating Tumor Cells and Overall Survival in Patients with Solid Tumors
9/19/2018
ApoCell, Inc. announced today the publication of biomarker results from the BEACON Phase 3 clinical trial that utilized Apocell's proprietary circulating tumor cell enrichment system, ApoStream®.